Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.
Target Price
The average target price of ARX.AX is 0.79 and suggests 14% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio
Buy
Sell